Pancreatic: 4 agencies, 2014–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused pancreatic: all 4 decisive outcomes across 3 agencies were positive or positive with restrictions.
Assessment has run over 10.6 years, from 15 Oct 2014 at HAS (France) to 29 May 2025 at CONITEC (Brazil).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — SMC (Scotland), PHARMAC (New Zealand) and AWMSG (Wales) among them — hold no record for pancreatic at all.
Not every gap is a refusal: for pancreatic, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 7 records date from 2023 or later.
2 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess pancreatic, on 15 Oct 2014; CONITEC (Brazil) did not open a file until 29 May 2025 — an unusually long tail of 10.6 years between the earliest and latest system to look at it.
2 of the 4 agencies here assessed pancreatic more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed pancreatic.
The full ledger for pancreatic reads 4 recommended, 2 other and 1 withdrawn.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 29 May 2025 | Tratamento de reposição enzimática de pacientes com insuficiência pancreática exócrina. | incorporated into SUS | source |
| CIPM (Spain) | 21 May 2025 | Indicaciones terapéuticas autorizadas: MEKRAZYM es una terapia sustitutiva indicada para el tratamiento de la insuficien… | financed by the SNS · art. 92 c, d | source |
| PBAC (Australia) | 2024 | Cystic fibrosis | The PBAC rescinded the November 2020 recommendation for pancreatic extract. | source |
| HAS (France) | 11 Mar 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 15 Oct 2014 | Listing (Transparency Committee) | ASMR V | source |
2 further decisions for pancreatic, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- trastuzumab — also decided by CONITEC in 2025Q2
- satralizumab — also decided by CONITEC in 2025Q2
- bosutinib — also decided by CONITEC in 2025Q2
- romiplostim — also decided by CONITEC in 2025Q2
- lanadelumab — also decided by CONITEC in 2025Q2
- nivolumab — also decided by CONITEC in 2025Q2
Coverage: 7 decisions for pancreatic from 4 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class A09A — Digestives. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.